Answers are grounded in this paper and cite their sources.
A 5-year-old affected male had following phenotypes: autism, motor stereotypy, developmental regression, staring gaze, absent speech, and behavioral abnormality. The biochemical testing was normal and genetic testing identified a de novo pathogenic variant in ITSN1 gene in the proband. To our knowledge, this is the second report that elucidates the role of ITSN1 gene in an autosomal dominant neurodevelopmental disorder. Neurodevelopmental disorders (NDD) include intellectual disability (ID) characterized by defects in adaptive function and intellectual abilities and autism spectrum disorders (ASD) are defined as early dysfunction in social interactions, communication deficits, and the presence of repetitive and restricted behaviors.1 Autism spectrum disorder are common childhood onset neurodevelopmental disorders with estimated worldwide prevalence of 58.6 million cases among children and young people 20 years and younger.2 Recent advancement in next generation sequencing (NGS) has enhanced the understanding of the many Mendelian neurodevelopmental conditions. We report a 5-year-old male with autism, motor stereotypy, developmental regression, staring gaze, absent speech, and behavioral abnormality due to de novo loss of function pathogenic variant in long isoform of ITSN1 gene. The ITSN1 has been recently identified as a candidate gene for autosomal dominant neurodevelopmental disorder spectrum.1 To our knowledge, this is the second report that elucidates the role of ITSN1 gene in an autosomal dominant neurodevelopmental disorder. A 5-year-old affected male was referred to Undiagnosed Rare Disease Clinic (URDC) due to history of severe nonverbal ASD complicated by significant language regression. The following phenotypes were observed in the patient: autism, motor stereotypy, developmental regression, staring gaze, absent speech, and behavioral abnormality. There was no history of seizures or congenital malformations in the patient. This study was approved by the Institutional Review Boards (IRB# 2005902680) of Indiana University. Written informed consent was obtained from all participating family members. The following biochemical testing: congenital disorders of glycosylation (CDG), purine-pyrimidine panel, plasma amino acids, creatine panel and a chromosomal microarray analysis (CMA) were all normal. Furthermore, autism/ID expanded panel testing was performed in both parents and proband at clinical lab that identified a de novo pathogenic variant [hg 19; chr21:35190690; NM_003024.2; c.2847G>A: p.(Trp949*)] in ITSN1 gene in the proband (Figure 1A). This variant lies in the SH3 domain of intersectin 1 protein (Figure 1B). Due to the location of the nonsense variant, the mutant mRNA is predicted to be targeted by nonsense-mediated decay. The variant is absent in various public databases, including gnomAD (v4.0 and v2.1.1) TOPMed, and All of Us. It has a high CADD Phred score (37). This variant is classified as pathogenic according to ACMG guidelines (PVS1, PS2, PM2, and PP4). The ITSN1 gene (Intersectin 1) is located on chromosome 21q22.11 and encodes a cytoplasmic membrane-associated protein involved in many cellular processes such as exocytosis and endocytosis.3 ITSN1 gene plays an important role in the development of brain in causing NDD. Very limited clinical data is available for ITSN1 related autosomal dominant NDD. To date, only one study has been published that identified eight de novo variants in 10 patients with autosomal dominant NDD. Among all of the reported patients with de novo ITSN1 variants, autistic behavior, global developmental delay, delayed speech and language development were common, but for additional phenotypes there is a high level of heterogeneity. Consistent with previously reported patients,1 we observed autism, global developmental delay, speech and behavioral abnormalities in our patient but we did not observe any other congenital abnormality in our patient. The ITSN1 variant p.(Trp949*) identified in this study lies in the SH3 domain of and in close proximity of previously known variants [p.(Met948Val*41) and p.(Tyr965*)] for ASD.1, 4 Furthermore, biallelic variants in the ITSN1 gene have also been known to cause autosomal recessive intellectual disability (ARID).5 In summary, we report on a new pathogenic loss of function variant [c.2847G>A: p.(Trp949*)] in the ITSN1 gene and expand the genetic and phenotypic spectrum of the recently identified autosomal dominant neurodevelopmental disorder. K.L. drafted the manuscript. Lili Mantcheva (project manager) and K.T. coordinated with family, collected the samples and clinical data of the family. E.C. and TE.W. evaluated the patient clinically. F.V. analyzed the data and designed the study. E.C. and F.V. edited the manuscript. We thank the family members for participating in this study. This study is funded in part by the Indiana University Grand Challenge Precision Health Initiative. The authors declare no conflict of interest. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/cge.14497. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
No takes yet. Share an insight, caveat, or question.
Liaqat et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: